Entero Therapeutics to Present Corporate Update at 2024 BIO International Convention
Entero Therapeutics Inc. (ENTO)
Company Research
Source: GlobeNewswire
BOCA RATON, Fla., May 22, 2024 (GLOBE NEWSWIRE) -- Entero Therapeutics, Inc. (formerly First Wave BioPharma, Inc.) (Nasdaq: ENTO) (“Entero” or the “Company”), a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that it will present at the 2024 BIO International Convention which will be held June 3-6, 2024, in San Diego, California. Event:BIO International ConventionDate:June 3-6, 2024Presentations:Tuesday, June 4 at 10:30 a.m. PDTLocation:Company Presentation Theater 4Registration: https://convention.bio.org/registration To schedule a meeting at the BIO International Convention with Entero, please submit a meeting request through the BIO One-on-One Partnering™ platform. For more information about Entero Therapeutics, visit www.enterothera.com and connect on X and LinkedIn. About Entero Therapeutics Entero Therapeutics, Inc. (formerly First Wave BioPharma) is a late cli
Show less
Read more
Impact Snapshot
Event Time:
ENTO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ENTO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ENTO alerts
High impacting Entero Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
ENTO
News
- Entero Therapeutics Signs Letter of Intent to License and Commercialize Remote Patient and Machine Vision Clinical Trial Management Platform from Data Vault HoldingsGlobeNewswire
- Entero Therapeutics, Inc. Receives Nasdaq Notification Regarding Delayed Form 10-QGlobeNewswire
- Entero Therapeutics' Chairman and CEO James Sapirstein Provides Business Update with Focus on Latiglutenase Development Program [Yahoo! Finance]Yahoo! Finance
- Entero Therapeutics’ Chairman and CEO James Sapirstein Provides Business Update with Focus on Latiglutenase Development ProgramGlobeNewswire
- Entero Therapeutics Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $1.9 Million Gross Proceeds [Yahoo! Finance]Yahoo! Finance
ENTO
Sec Filings
- 9/11/24 - Form 8-K
- 9/10/24 - Form 8-K
- 9/3/24 - Form 8-K
- ENTO's page on the SEC website